President and Chief Operating Officer · SUTRO BIOPHARMA, INC. (STRO)

R.Ph. Jane Chung

FY2023 is the first fiscal year CompBrief holds for R.Ph. Jane Chung as a named executive officer of SUTRO BIOPHARMA; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,497,121

Salary $506,217Stock awards $434,225

4th of 5 named executive officers at Sutro Biopharma by FY2023 total.

5 named officers on file for SUTRO BIOPHARMA, FY2023

R.Ph. Jane Chung’s pay file — $29

  • 1 fiscal year of pay, line by line
  • STRO’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how SUTRO BIOPHARMA’s whole pay program stands against its peers

  • SUTRO BIOPHARMA’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on STRO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2025 (DEF 14A).

Free

Get R.Ph. Jane Chung’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

R.Ph. Jane Chung compensation by year

SUTRO BIOPHARMA Summary Compensation Table · the one fiscal year held
In US dollars, as SUTRO BIOPHARMA reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$506,217
Stock awards$434,225
Option awards$236,882
Non-equity incentive$227,798
Pension and deferred compensation$0
All other$92,000
Total$1,497,121

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SUTRO BIOPHARMA, INC. DEF 14A filed April 25, 2025, accession 0000950170-25-058774, and prior-year filings. Open the filing on EDGAR.

How this page was built: the SUTRO BIOPHARMA, INC. filed document, accession 0000950170-25-058774. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2025.

SUTRO BIOPHARMA’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Anne BorgmanChief Medical Officer$2,335,549
William NewellChief Executive Officer$2,129,979
Hans-Peter GerberChief Scientific Officer$1,626,976
R.Ph. Jane Chung · this pagePresident and Chief Operating Officer$1,497,121
Edward AlbiniChief Financial Officer$1,018,488

The full SUTRO BIOPHARMA compensation record

free company brief

This page is one person within SUTRO BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the SUTRO BIOPHARMA proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SUTRO BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

R.Ph. Jane Chung's compensation dossier · One-time report. No refunds.